Medium-Term Management Plan Targets for the Fiscal Year Ending March 2019 (Net Sales: ¥3.788 billion; Operating Profit: ¥4.7 billion; ROE: 10.4%)
First written in FY2017. 2 of 6 entries say "Achieved", first in FY2021. Latest entry: FY2022.
The whole theme swung hardest in 2021: 5 of 20 companies on the "Worse" side.
7 other companies' latest entry also says "Achieved".
- FY2022AchievedAnnual report
「Net sales were ¥42,996 million, operating income was ¥8,387 million and ROE was 14.3%, achieving all targets.」
Against targets for the fiscal year ending March 2022 of net sales of ¥40,400 million, operating income of ¥6,370 million and ROE of 11.5%, all targets were stated as achieved. - FY2021AchievedAnnual report
「To prepare for the second and third waves of COVID-19, we established a system for increasing production of COVID-19 genetic testing reagents and achieved a stable supply of testing reagents. As a result, despite the impact of interruptions to various health-checkup and screening programs and a decline in outpatient numbers, net sales were ¥38,667 million, operating income was ¥6,612 million and ROE was 12.9%, achieving all targets.」
For the fiscal year ending March 2021, against targets of net sales of ¥37,100 million, operating income of ¥5,540 million and ROE of 11.1%, actual results were net sales of ¥38,667 million, operating income of ¥6,612 million and ROE of 12.9%, with all targets achieved. - FY2020Fiscal year ending March 2020: net sales below target; operating income and ROE achievedAnnual report
「The company had aimed to achieve net sales of ¥36,800 million, operating income of ¥4,350 million and ROE of 9.5% in the fiscal year ending March 2020. Actual results were net sales of ¥36,585 million, operating income of ¥4,622 million and ROE of 9.9%. Although net sales did not grow as expected, operating income and ROE achieved their targets due to higher profit accompanying the increase in sales.」
The company stated that the net sales target for the fiscal year ending March 2020 was not achieved, while operating income and ROE exceeded their targets. - FY2019Net sales below target; operating income and ROE achievedAnnual report
「The Group had aimed to achieve net sales of ¥36,760 million, operating income of ¥4,200 million and ROE of 9.2% in the fiscal year ending March 2019 as objective indicators for assessing the achievement of its management policies, strategies and targets. Actual results were net sales of ¥35,761 million, operating income of ¥4,611 million and ROE of 10.3%. Net sales fell short of the target mainly because overseas sales did not grow as expected, while operating income and ROE achieved their targets due to an improvement in the cost-of-sales ratio resulting from changes in the sales mix and a decline in selling, general and administrative expenses.」
Regarding the revised targets for the fiscal year ending March 2019, net sales fell short, while operating income and ROE achieved their targets. - FY2018SoftenedAnnual report
「Under the medium-term management plan, the company had aimed to achieve net sales of ¥37,880 million, operating income of ¥4,700 million and ROE of 10.4% in the fiscal year ending March 2019, the final year of the plan. However, mainly because the forecast for overseas sales was revised downward, the forecasts for net sales and operating income were lowered. The outlook for the fiscal year ending March 2019 was net sales of ¥36,760 million, up 5.1% year on year, operating income of ¥4,200 million, up 20.7%, and ROE of 9.2%.」
The targets for the fiscal year ending March 2019 were lowered from net sales of ¥37,880 million to ¥36,760 million, operating income of ¥4,700 million to ¥4,200 million, and ROE of 10.4% to 9.2%. The stated primary reason was the downward revision to overseas sales. - FY2017First statedAnnual report
「In accordance with the basic policy of the new management vision “EIKEN ROAD MAP 2009,” formulated in March 2009, the Group established priority measures and, under its medium-term management plan, aimed to achieve net sales of ¥37,880 million, operating income of ¥4,700 million and ROE of 10.4% in the fiscal year ending March 2019, the final year of the plan.」
The medium-term management plan’s final-year targets for net sales, operating income and ROE are stated as independent numerical targets for the first time.